Association of mitotic regulation pathway polymorphisms with pancreatic cancer risk and outcome

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 1, 2010, Pages 251-257

  Couch, Fergus J ^a   Wang, Xianshu ^a   Bamlet, William R ^a   De Andrade, Mariza ^a   Petersen, Gloria M ^a   McWilliams, Robert R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APC GENE; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE; GENE LOCUS; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MITOSIS; NIN GENE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADENOCARCINOMA; AGED; BODY MASS INDEX; CYTOSKELETAL PROTEINS; GENES, APC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; MITOSIS; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 74549122398     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0629     Document Type: Article

References (29)

1. Petersen GM, Hruban RH. Familial pancreatic cancer: where are we in 2003? J Natl Cancer Inst 2003;95:180-1.
2. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007;16:342-6.
3. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333:970-4.
4. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119:1447-53.
5. Lingle WL, Barrett SL, Negron VC, et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A 2002;99:1978-83.
6. Weyrer K, Feichtinger H, Haun M, et al. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Lab Invest 1996;74: 279-89.
7. Nowak NJ, Gaile D, Conroy JM, et al. Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet 2005;161:36-50.
8. Li JJ, Li SA. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther 2006;111:974-84.
9. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/ BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-93.
10. Mundt KE, Golsteyn RM, Lane HA, Nigg EA. On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. Biochem Biophys Res Commun 1997; 239:377-85.
11. Zhu J, Abbruzzese JL, Izzo J, Hittelman WN, Li D. AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. Cancer Genet Cytogenet 2005;159:10-7.
12. Bettencourt-Dias M, Giet R, Sinka R, et al. Genome-wide survey of protein kinases required for cell cycle progression. Nature 2004;432: 980-7.
13. Kittler R, Putz G, Pelletier L, et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature 2004;432:1036-40.
14. D'Assoro AB, Lingle WL, Salisbury JL. Centrosome amplification and the development of cancer. Oncogene 2002;21:6146-53.
15. Brinkley BR. Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell Biol 2001;11:18-21.
16. Salisbury JL, Lingle WL, White RA, Cordes LE, Barrett S. Microtubule nucleating capacity of centrosomes in tissue sections. J Histochem Cytochem 1999;47:1265-74.
17. Marx J. Cell biology. Do centrosome abnormalities lead to cancer? Science 2001;292:426-9.
18. Olson JE, Wang X, Goode EL, et al. Variation in genes required for normal mitosis and risk of breast cancer. Breast Cancer Res Treat 2009 Apr [Epub ahead of print].
19. Wang X, Fredericksen ZS, Vierkant RA, et al. Association of genetic variation in mitotic kinases with breast cancer risk. Breast Cancer Res Treat 2009 Apr 30. [Epub ahead of print].
20. McWilliams RR, Bamlet WR, de Andrade M, Rider DN, Cunningham JM, Petersen GM. Nucleotide excision repair pathway polymorphisms and pancreatic cancer risk: evidence for role of MMS19L. Cancer Epidemiol Biomarkers Prev 2009;18:1295-302.
21. Stevens RJ, Roddam AW, Spencer EA, et al. Factors associated with incident and fatal pancreatic cancer in a cohort of middle-aged women. Int J Cancer 2009;124:2400-5.
22. Ahlgren JD. Epidemiology and risk factors in pancreatic cancer. Semin Oncol 1996;23:241-50.
23. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
24. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
25. Liu W, Dong X, Mai M, et al. Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating β-catenin/TCF signalling. Nat Genet 2000;26:146-7.
26. Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor β-catenin mutations. Am J Pathol 2002;160:1361-9.
27. Zeng G, Germinaro M, Micsenyi A, et al. Aberrant Wnt/β-catenin signaling in pancreatic adenocarcinoma. Neoplasia 2006;8:279-89.
28. Julkunen K, Makinen K, Karja V, Kosma VM, Eskelinen M. α-, β- and chi-catenin expression in human pancreatic cancer. Anticancer Res 2003;23:5043-7.
29. Sato N, Mizumoto K, Nakamura M, et al. Correlation between centrosome abnormalities and chromosomal instability in human pancreatic cancer cells. Cancer Genet Cytogenet 2001;126:13-9.